drugset
drugset / Trial / NCT02288481

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

NCT02288481 ↗

Phase 1 Completed 48 enrolled Global Alliance for TB Drug Development
RandomizedSingle-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.

Timeline

Start
2015-01
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TBA-354 Small molecule 10 mg Oral
Subject TBA-354 Small molecule 25 mg Oral
Subject TBA-354 Small molecule 60 mg Oral
Subject TBA-354 Small molecule 150 mg Oral
Subject TBA-354 Small molecule 400 mg Oral
Subject TBA-354 Small molecule 1000 mg Oral

Indications

tuberculosis